30.21
+2.41%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Amylyx Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Amylyx Pharmaceuticals is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AMLX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $144.7m. At that date it held total assets of $332.6m and shareholders' equity of $305.3m.
Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases. We are advancing a pipeline in which we have matched investigational therapies with diseases for which we believe these therapies can make the greatest impact, based on well-defined mechanistic rationales, clear clinical outcomes and biomarkers, and rigorous preclinical data, agnostic of modality. Our current pipeline is represented in the table below.
Our lead investigational asset is avexitide, a first-in-class glucagon-like peptide-1, or GLP-1, receptor antagonist. Avexitide has been evaluated as a treatment for PBH and congenital hyperinsulinism, or Congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. The U.S. Food and Drug Administration, or the FDA, has granted avexitide Breakthrough Therapy Designation for both PBH and HI, Rare Pediatric Disease Designation in Congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Jan 2022
- Employees
- 136
- Website
- amylyx.com ↗
- Head office
- 55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA, 02142
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. George MilneChair of the Board of Directors$143,329
- Mr. Joshua CohenCo-Chief Executive Officer, Director, since 2014$6.5m
- Mr. Justin KleeCo-Chief Executive Officer, Director, since 2014$6.5m
- Mr. James FratesChief Financial Officer$2.5m
- Ms. Gina MazzarielloChief Legal Officer and General Counsel$2.3m
- Dr. Camille BedrosianChief Medical Officer$2.4m
- Ms. Karen FirestoneIndependent Director$87,704
- Mr. Paul FonteyneIndependent Director$94,153
- Ms. Daphne QuimiIndependent Director$100,204
- Dr. Bernhardt ZeiherIndependent Director$159,847
- Ms. Lindsey AllenIR Contact Officer, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 26
- Environment
- 24
- Social
- 28
- Governance
- 25
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Amylyx Pharmaceuticals focuses on neurodegenerative disease treatments with AMX003 for ALS.
- The company has 262 full-time employees in Cambridge, Massachusetts.
- AMX0035 leverages UPR-Bax apoptosis inhibition for multiple neurodegenerative diseases.
Weaknesses
- Amylyx's IPO occurred in January 2022 with limited commercial history.
- The company has only one product candidate AMX003 for ALS treatment.
- AMX0114 is still in development as an antisense oligonucleotide.
Opportunities
- AMX0035 could expand to other neurodegenerative diseases beyond ALS.
- The firm's ASO development includes AMX0114 targeting calpain-2 for ALS.
- Amylyx can leverage its neurodegenerative disease expertise for new therapies.
Threats
- AMX0035 development faces competition in neurodegenerative disease treatments.
- Regulatory approval delays could impact AMX003 commercialization.
- The company's reliance on a single product candidate AMX003 poses market risk.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.